YU59102A - JEDINJENJA KORISNA ZA LEČENJE ILI PREVENCIJU OBOLJENJA U KOJEM UČESTVUJE ALFA-2β-ADRENOCEPTOR - Google Patents

JEDINJENJA KORISNA ZA LEČENJE ILI PREVENCIJU OBOLJENJA U KOJEM UČESTVUJE ALFA-2β-ADRENOCEPTOR

Info

Publication number
YU59102A
YU59102A YU59102A YUP59102A YU59102A YU 59102 A YU59102 A YU 59102A YU 59102 A YU59102 A YU 59102A YU P59102 A YUP59102 A YU P59102A YU 59102 A YU59102 A YU 59102A
Authority
YU
Yugoslavia
Prior art keywords
adrenoceptor
alpha
prevention
treatment
disease mediated
Prior art date
Application number
YU59102A
Other languages
English (en)
Serbo-Croatian (sh)
Inventor
Siegfried Wurster
Mia Engstrom
Liisa Huovinen
Sari Kalliokoski
Leila Kelanne
Eeva-Liisa Savola
Original Assignee
Oy Juvantia Pharma Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20000303A external-priority patent/FI20000303A0/fi
Application filed by Oy Juvantia Pharma Ltd. filed Critical Oy Juvantia Pharma Ltd.
Publication of YU59102A publication Critical patent/YU59102A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
YU59102A 2000-02-11 2001-02-07 JEDINJENJA KORISNA ZA LEČENJE ILI PREVENCIJU OBOLJENJA U KOJEM UČESTVUJE ALFA-2β-ADRENOCEPTOR YU59102A (sh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18202100P 2000-02-11 2000-02-11
FI20000303A FI20000303A0 (fi) 2000-02-14 2000-02-14 Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet

Publications (1)

Publication Number Publication Date
YU59102A true YU59102A (sh) 2005-11-28

Family

ID=26160944

Family Applications (1)

Application Number Title Priority Date Filing Date
YU59102A YU59102A (sh) 2000-02-11 2001-02-07 JEDINJENJA KORISNA ZA LEČENJE ILI PREVENCIJU OBOLJENJA U KOJEM UČESTVUJE ALFA-2β-ADRENOCEPTOR

Country Status (22)

Country Link
EP (1) EP1253926A1 (is)
JP (1) JP2003522148A (is)
KR (1) KR20020080413A (is)
AU (1) AU780802B2 (is)
BR (1) BR0108221A (is)
CA (1) CA2399421A1 (is)
CZ (1) CZ20022884A3 (is)
EA (1) EA200200846A1 (is)
EE (1) EE200200435A (is)
GE (1) GEP20043356B (is)
HR (1) HRP20020746A2 (is)
HU (1) HUP0300032A3 (is)
IL (1) IL151017A0 (is)
IS (1) IS6476A (is)
MX (1) MXPA02007454A (is)
MY (1) MY133957A (is)
NO (1) NO20023773D0 (is)
NZ (1) NZ520500A (is)
PL (1) PL357872A1 (is)
SK (1) SK11472002A3 (is)
WO (1) WO2001058454A1 (is)
YU (1) YU59102A (is)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004535467A (ja) * 2001-07-20 2004-11-25 オサケユイチア ユバンティア ファーマ リミティド α−２Ｂ−アドレナリン受容体が介在する疾患を治療又は予防するために有用な化合物
FI116940B (fi) 2001-07-20 2006-04-13 Juvantia Pharma Ltd Oy Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8416432D0 (en) * 1984-06-28 1984-08-01 Wyeth John & Brother Ltd Benzoquinolizines
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US6150389A (en) * 1994-07-11 2000-11-21 Allergan Sales, Inc. Comformationally rigid bicyclic and adamantane derivatives useful as α2 -adrenergic blocking agents

Also Published As

Publication number Publication date
AU3551001A (en) 2001-08-20
NO20023773L (no) 2002-08-09
KR20020080413A (ko) 2002-10-23
NO20023773D0 (no) 2002-08-09
EE200200435A (et) 2003-12-15
GEP20043356B (en) 2004-04-13
HUP0300032A2 (en) 2003-05-28
NZ520500A (en) 2005-01-28
MXPA02007454A (es) 2004-08-23
PL357872A1 (en) 2004-07-26
EP1253926A1 (en) 2002-11-06
AU780802B2 (en) 2005-04-21
CZ20022884A3 (cs) 2003-02-12
BR0108221A (pt) 2003-03-05
HUP0300032A3 (en) 2006-01-30
IS6476A (is) 2002-07-19
IL151017A0 (en) 2003-02-12
MY133957A (en) 2007-11-30
WO2001058454A1 (en) 2001-08-16
EA200200846A1 (ru) 2002-12-26
SK11472002A3 (sk) 2003-02-04
CA2399421A1 (en) 2001-08-16
JP2003522148A (ja) 2003-07-22
HRP20020746A2 (en) 2004-12-31

Similar Documents

Publication Publication Date Title
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
HK1069339A1 (en) Substituted diketopiperazines as oxytocin antagonists
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
WO2005011653A3 (en) Pyridazine derivatives and their use as therapeutic agents
WO2005011655A3 (en) Pyridazine derivatives and their use as therapeutic agents
WO2003048164A3 (en) Adenosine a2a receptor antagonists
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
WO2004029031A3 (en) Therapeutic piperazine compounds
MXPA04005209A (es) Antagonistas del receptor de adenosina a2a.
WO2001064645A3 (en) Derivatives of quinoline as alpha-2 antagonists
LV12291A (lv) Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
MXPA03005601A (es) Nuevos compuestos y composiciones como inhibidores de catepsina.
GB9917822D0 (en) Nmda antagonist
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
CA2432177A1 (en) Drug for prevention and/or therapy of endometriosis
YU59102A (sh) JEDINJENJA KORISNA ZA LEČENJE ILI PREVENCIJU OBOLJENJA U KOJEM UČESTVUJE ALFA-2β-ADRENOCEPTOR
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
SG165152A1 (en) Chemokine receptor antagonists and methods of use thereof
DE60004996D1 (de) Aminotetralin derivate zur therapie der kardiovaskulären erkrankungen
YU24603A (sh) Novi farmaceutski preparati koji sadrže epinastin i pseudoefedrin
AU2002211217A1 (en) Method of treating stroke
DE60104288D1 (de) Antivirale therapie
WO2004034967A3 (en) 2,4,6-triaminopyrimidines for the treatment of depression and/or anxiety